Case Reports
Prevention of doxorubicin-induced congestive heart failure by continuous intravenous infusion in multiple myeloma; a case report and review of the literature
Affiliations
- PMID: 2030807
Item in Clipboard
Case Reports
Prevention of doxorubicin-induced congestive heart failure by continuous intravenous infusion in multiple myeloma; a case report and review of the literature
Neth J Med.
1991 Feb.
Abstract
Doxorubicin (Adriamycin) is an effective antitumour drug. Its major side-effect, cardiotoxicity, is markedly reduced by giving it as a continuous infusion, as illustrated by a case history and review of the literature.
Similar articles
-
[Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].Vnitr Lek. 1994 Aug;40(8):506-12. Vnitr Lek. 1994. PMID: 7941437 Czech.
-
Adriamycin (doxorubicin) cardiotoxicity: a review.West J Med. 1979 Nov;131(5):364-8. West J Med. 1979. PMID: 394479 Free PMC article. Review.
-
[Adriamycin (doxorubicin)].Gan To Kagaku Ryoho. 2001 Oct;28(10):1331-8. Gan To Kagaku Ryoho. 2001. PMID: 11681238 Review. Japanese.
-
[Treatment of multiple myeloma resistant to alkylating agents with dexamethasone, vincristine and adriamycin in continuous infusion].Rev Rhum Mal Osteoartic. 1987 Jun;54(6):477-9. Rev Rhum Mal Osteoartic. 1987. PMID: 3616472 French. No abstract available.
-
Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats.Cancer Res. 1977 Aug;37(8 Pt 1):2705-13. Cancer Res. 1977. PMID: 872096 No abstract available.
Cited by
-
Tobacco mosaic virus-based protein nanoparticles and nanorods for chemotherapy delivery targeting breast cancer.J Control Release. 2016 Jun 10;231:103-13. doi: 10.1016/j.jconrel.2016.02.045. Epub 2016 Mar 3. J Control Release. 2016. PMID: 26941034 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical